Peptide register

Synthetic analogue of the Semax peptide family; no registered human trials and no approval.

Peptide preparation from porcine brain tissue; prescription medicine in some countries, not approved in the US or EU.

Not approved in the US; national approvals only

Nonapeptide first described in the 1970s; no marketing authorisation in any market.

Angiotensin IV-derived peptidomimetic; never given to a person in a trial, and its key mechanism paper was retracted.

Acetylated and amidated Selank variant sold by vendors; no studies of its own, one analytical paper, no PubChem entry, no approval.

The parent peptide Selank is registered as a medicine in Russia only; this modified form is not, as the registration covers only the exact sequence. The manufacturer confirmed non-prescription supply in 2017

Acetylated and amidated Semax variant sold by vendors; no studies of its own, only one analytical paper, and no approval.

The unmodified parent peptide is registered as a medicine in Russia; this variant is not, as the registration covers only the exact Semax sequence

Ciliary neurotrophic factor-derived peptide studied in rodents; not the cell-cycle protein of the same name, never tested in people.

Spadin-derived TREK-1 channel blocker peptide; preclinical only, no approval anywhere.

Synthetic tuftsin analogue peptide; registered as a prescription medicine in Russia.

Russia only

Synthetic ACTH (4-10) fragment analogue; registered as a prescription medicine in Russia.

Russia only

Acetylated octapeptide from the human SNAP-25 protein, sold as a cosmetic ingredient; not a medicine and not a copper peptide.

Vasoactive intestinal peptide; aviptadil is a prescription medicine in several European markets, but only as a fixed combination.

Prescription-only and approved solely as a fixed combination with phentolamine, in Germany, Denmark, Finland, France, Norway, Sweden and the UK